Detalhe da pesquisa
1.
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.
Blood
; 120(2): 376-85, 2012 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22451422
2.
Clonal competition with alternating dominance in multiple myeloma.
Blood
; 120(5): 1067-76, 2012 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-22498740
3.
Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma.
Blood Cancer Discov
; 5(1): 34-55, 2024 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37767768
4.
Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.
Blood Cancer Discov
; 2(4): 354-369, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34258584
5.
Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression.
Blood Cancer Discov
; 1(1): 68-81, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32954360
6.
Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression.
Nat Commun
; 9(1): 4832, 2018 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30510245
7.
IAP antagonists induce anti-tumor immunity in multiple myeloma.
Nat Med
; 22(12): 1411-1420, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27841872